文献速递乳腺癌支持与姑息治疗

乳腺癌化疗期间膳食补充剂使用与生存结局的辅助研究

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221).
PubMed 文献 · J Clin Oncol · 2019-12-19

该研究基于SWOG S0221随机试验的辅助前瞻性队列,评估乳腺癌患者化疗前后使用膳食补充剂与复发和生存的关联。

要点

  • 化疗前后使用维生素B12与较差无病生存(adjHR 1.83)和总生存(adjHR 2.04)显著相关。
  • 化疗期间使用铁剂与复发风险显著增加相关(adjHR 1.79)。

核心结论

  • 乳腺癌患者化疗前后使用抗氧化剂及其他膳食补充剂与生存结局的关联,支持在化疗期间除复合维生素外谨慎使用补充剂的建议。

研究设计与样本

  • 前瞻性辅助研究纳入SWOG S0221随机试验中接受环磷酰胺、多柔比星和紫杉醇治疗的乳腺癌患者,共1134例,在注册时和治疗期间询问补充剂使用情况,采用Cox比例风险回归调整临床和生活方式变量,以入组后6个月为界标进行复发和生存分析。

主要发现

  • 复合维生素使用与生存结局无关。

临床怎么用

  • 肿瘤内科医生应告知乳腺癌患者,化疗期间除复合维生素外,谨慎使用抗氧化剂、维生素B12和铁剂等膳食补充剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Despite reported widespread use of dietary supplements during cancer treatment, few empirical data with regard to their safety or efficacy exist. Because of concerns that some supplements, particularly antioxidants, could reduce the cytotoxicity of chemotherapy, we conducted a prospective study ancillary to a therapeutic trial to evaluate associations between supplement use and breast cancer outcomes. METHODS: Patients with breast cancer randomly assigned to an intergroup metronomic trial of cyclophosphamide, doxorubicin, and paclitaxel were queried on their use of supplements at registration and during treatment (n =1,134). Cox proportional hazards regression adjusting for clinical and lifestyle variables was used. Recurrence and survival were indexed at 6 months after enrollment using a landmark approach. RESULTS: There were indications that use of any antioxidant supplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was associated with an increased hazard of recurrence (adjusted hazard ratio [adjHR], 1.41; 95% CI, 0.98 to 2.04; P = .06) and, to a lesser extent, death (adjHR, 1.40; 95% CI, 0.90 to 2.18; P = .14). Relationships with individual antioxidants were weaker perhaps because of small numbers. For nonantioxidants, vitamin B12 use both before and during chemotherapy was significantly associated with poorer disease-free survival (adjHR, 1.83; 95% CI, 1.15 to 2.92; P < .01) and overall survival (adjHR, 2.04; 95% CI, 1.22 to 3.40; P < .01). Use of iron during chemotherapy was significantly associated with recurrence (adjHR, 1.79; 95% CI, 1.20 to 2.67; P < .01) as was use both before and during treatment (adjHR, 1.91; 95% CI, 0.98 to 3.70; P = .06). Results were similar for overall survival. Multivitamin use was not associated with survival outcomes. CONCLUSION: Associations between survival outcomes and use of antioxidant and other dietary supplements both before and during chemotherapy are consistent with recommendations for caution among patients when considering the use of supplements, other than a multivitamin, during chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ambrosone CB, Zirpoli GR, Hutson AD, et al. Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2019. PMID: 31855498. doi:10.1200/JCO.19.01203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。